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ASSOCIATION BETWEEN ANTIBODIES TO THE MR 67,000 
ISOFORM OF GLUTAMATE DECARBOXYLASE (GAD) AND 
TYPE 1 (INSULIN-DEPENDENT) DIABETES MELLITUS WITH 
COEXISTING AUTOIMMUNE POLYENDOCRINE 
SYNDROME TYPE II 
J O C H E N S E I S S L E R 1 , S A B I N E B I E G 1 , N A D J A Y A S S I N 1 , L U D W I G M A U C H 2 , W O L F G A N G 
N O R T H E M A N N 2 , B E R N H A R D O. B O E H M 3 A N D W E R N E R A . S C H E R B A U M 1 
1 D e p a r t m e n t of I n t e r n a l M e d i a n e III, University of L e i p z i g , D - 0 4 1 0 3 L e i p z i g , 2 D e p a r t m e n t M o l e c u l a r B i o l o g y , E L I A S , D - 7 9 I I 4 
F r e i b u r g , 3 D e p a r t m e n t I n t e r n a l M e d i a n e I , University of U l m , D - 8 9 0 8 1 U l m , G e r m a n y 
( R e c e i v e d 1 September 1 9 9 4 ; i n final f o r m 2 9 November 1994) 
By using an immunoprecipitation assay, we analysed reactivity of autoantibodies to human recombi-
nant G A D 6 5 and G A D 6 7 in sera from patients with autoimmune polyendocrine Syndrome Type II 
(APS II) with and without Type 1 (insulin-dependent) diabetes mellitus (IDDM) compared to patients 
with organ-specific autoimmunity. Overall antibodies to G A D 6 5 were correlated with I D D M in all 
study groups, whereas G A D 6 7 antibodies were associated with I D D M when APS II coexists. Antibod-
ies to G A D 6 5 and G A D 6 7 were detected in 13 (44.8%) and 7 (24.1%) out of 29 APS II patients with 
I D D M , but in only 4 (13.8%) and 2 (6.9%) out of 29 APS II patients without I D D M , respectively 
(p < 0.05). In short-standing I D D M (< 1 year), antibodies to G A D 6 7 were significantly more frequent 
in patients with APS II (5 of 9 [55.6%] subjects) compared to matched diabetic patients without 
coexisting polyendocrinopathy (1 of 18 [5.6%] subjects) (p < 0.02). The levels of G A D 6 5 
(142±90 AU) and G A D 6 7 antibodies (178±95 AU) were significantly higher in patients with poly-
glandular disease than in patients with isolated I D D M (91 ±85 A U and 93 ±57 AU) (p < 0.02). 
Interestingly, all 11 G A D 6 7 antibody positive subjects also had G A D 6 5 antibodies (p < 0.0001), and in 
10 of 11 ant i -GAD 6 7 positive sera the G A D 6 7 antibodies could be blocked by either G A D 6 7 or G A D 6 5 , 
suggesting the presence of cross-reactive autoantibodies. No correlation was observed between G A D 
antibodies and age, sex or any particular associated autoimmune disease, besides I D D M . G A D 
antibodies were present in only lof 6 (16.7%) patients with APS Type I, in 1 of 26 (3.9%) patients with 
autoimmune thyroid disease but in none of the patients with Addison's disease (n = 16), pernicious 
anaemia (n = 7) or normal controls (n = 50). Our data suggest distinct antibody specificities reactive to 
G A D isoforms in APS II and I D D M , which might reflect different mechanisms of autoimmune 
response in I D D M with coexisting autoimmune polyendocrine autoimmunity. 
K E Y WORDS: Insulin-dependent diabetes mellitus, autoimmune polyendocrine Syndrome, glutamic 
acid decarboxylase, autoimmunity. 
I N T R O D U C T I O N 
Autoimmune endocrinopathies are associated with 
lymphocytic Infiltration and chronic destruction of the 
afFected endocrine glands. The simultaneous involve-
ment of the adrenal cortex, the thyroid, the pancreatic 
islets or the gastric parietal cells in one patient defines 
the autoimmune polyglandular endocrine Syndrome 
Type II (APS I I ) 1 - 3 . In patients with APS II, a high 
prevalence of organ specific autoantibodies has been 
Correspondence to: Prof W.A. Scherbaum, Department of 
Internal Medicine III, University of Leipzig, Ph. Rosenthalstr. 
27, D-04103 Leipzig, Germany. Tel: (49) 341-397-560, Fax: (49) 
341-2613845. 
observed, including autoantibodies reactive to thyrop-
eroxidase and thyroglobulin, adrenal 17-alpha hydrox-
ylase or 21-hydroxylase and autoantibodies to the 
gastric proton pump H + / K + ATPase, respectively3'4. 
In Type 1 (insulin-dependent) diabetes mellitus 
( IDDM) with and without coexisting autoimmunity, 
cytoplasmic islet cell antibodies (ICA) have been 
described as valuable serological marker5-6. Recently it 
has been demonstrated that ICA react with heteroge-
nous islet antigens7"9 including the enzyme glutamate 
decarboxylase (GAD), which has been previously 
identified as one target antigen of autoantibodies di-
rected to the 64 K D islet cell protein 1 0 . Human G A D 
exists in two isoforms of M r 65,000 ( G A D 6 5 ) and M r 
67,000 ( G A D 6 7 ) that are encoded by two distinct 
231 
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genes11. The detection of autoantibodies to G A D 6 5 in 
70-80% of patients with newly-diagnosed I D D M and 
prediabetic individuals has clearly demonstrated that 
G A D 6 5 represents a major B-cell autoantigen in 
I D D M 1 2 1 3 . Apart from I D D M , high level G A D 6 5 and 
G A D 6 7 antibodies have been detected in Stiff-Man-
Syndrome (SMS), a rare neurological disorder, where 
about 60% of the non-tumor associated form are cor-
related with organ-specific autoimmunity 1 4. In SMS 
the humoral immunoreactivity to G A D is completely 
different from I D D M . The majority of G A D anti-
bodies from SMS patients react with both isoforms 
including linear epitopes of G A D 6 5 , whereas in I D D M 
the antibodies are predominantly directed to confor-
mation epitopes of G A D 6 5 9 ' 1 0 ' 1 4 . Considering these 
data on the heterogeneity of the immune response to 
G A D in different disorders it is of interest to establish 
the possible significance of antibodies to both G A D 
isoforms in APS II, which is frequently associated with 
I D D M . 
In this study, we examined the prevalence of anti-
bodies to human G A D 6 5 and G A D 6 7 among patients 
with isolated organ-specific autoimmunity and sub-
jects with APS. By means of an immunoprecipitation 
assay using human recombinant G A D proteins, we 
were able to demonstrate distinct patterns of autoanti-
body specificities in APS II and I D D M . Autoanti-
bodies to G A D 6 7 were mainly found in diabetic pa-
tients with APS II, which suggests differences in the 
autoimmune pathogenesis of I D D M with and without 
polyendocrine autoimmunity. 
M A T E R I A L A N D M E T H O D S 
P a t i e n t s 
Sera were studied from 58 patients with autoimmune 
polyendocrine Syndrome Type II. APS II was defined 
by the presence of at least two of the following dis-
eases: autoimmune Addison's disease, autoimmune 
thyroid disease, I D D M and pernicious anaemia, re-
spectively. 29 of these patients had overt I D D M with a 
duration of the disease from 0 to 26 years (mean 
duration of I D D M 9.1 years). Furthermore, sera were 
obtained from 6 non-diabetic patients with auto-
immune polyendocrine Syndrome Type I (APS I). A l l 
patients with APS I had mucocutaneous candidiasis, 
adrenal insufficiency and hypoparathyroidism. Pa-
tients with clinical overt autoimmune disease affecting 
one endocrine tissue who were only positive for organ-
specific autoantibodies to the respective endocrine 
gland served as controls. We tested 26 patients with 
autoimmune thyroid disease, including 14 patients 
with Hashimoto's thyroiditis and 12 patients with 
Graves' disease, 16 patients with autoimmune Add-
ison's disease and 7 patients with pernicious anaemia. 
Sera from 18 patients with recent-onset I D D M (0-1 
year) and 20 patients with long-standing I D D M (2-26 
years) matched for age, sex and duration of disease 
were used as controls. Part of these sera had been 
previously characterized for ICA and G A D anti-
bodies 1 2. 50 healthy individuals without a family his-
tory of endocrine diseases served as controls. Sera 
were coded, stored at - 20°C and tested in a blinded 
way in all assays. Informed consent was obtained from 
all patients and control subjects. 
D e t e c t i o n of a u t o a n t i b o d i e s t o h u m a n G A D 6 5 a n d 
G A D 6 7 
Antigen expression in a baculovirus system and the 
preparation of 3 5S-methionine labelled human recom-
binant G A D 6 5 and G A D 6 7 was performed as de-
scribed recently 1 2 , 1 5 . Membrane fractions of the re-
combinant proteins containing equal amounts of 
radiolabelled proteins (1 x 10 6 cpm) were precipitated 
with normal human serum. Then the precleared ex-
tracts were incubated with 25 ul of test serum for 8 h 
and immunoprecipitated with Protein A Sepharose 
(Pharmacia, Freiburg). Samples were washed, eluted 
and fluorographed as described 1 2. Gels were scanned 
by laser densitometry, the antibody levels were ex-
pressed in arbitrary units (AU) and calculated as fol-
lows: (unknown minus normal control)/(positive refer-
ence serum minus normal control) x 100. Sera were 
regarded as positive if G A D 6 5 or G A D 6 7 antibody 
levels were greater than 3 SD above the mean of 50 
normal sera (9.3 A U and 11.8 A U , respectively). In 
the First I D W Proficiency Program for the standardis-
ation of the G A D antibody assays, we achieved values 
of 100% for specificity, 83.3% sensitivity and 87,5% 
validity 1 6 . 
B l o c k i n g of G A D 6 7 a n t i b o d i e s 
To analyse cross-reactivity of G A D 6 7 antibodies with 
G A D 6 5 blocking experiment are performed in G A D 6 7 
antibody positive sera. Sera were incubated with mem-
brane fractions of either unlabelled human recombi-
nant G A D 6 7 or G A D 6 5 (50 p,g/serum) for 4 h at room 
temperature. Noninfected Sf9 cells were used as con-
trol. After preincubation sera were subjected to immu-
noprecipitation as described above. 
I m m u n o f l u o r e s c e n c e studies 
ICA were analysed by indirect immunofluorescence 
testing on cryostat sections of the pancreas from a 
organ donor with blood group 0 1 7 . Results were 
expressed in JDF-Units (IDW Proficieny Program 
Lab ID no 116). The detection limit in our laboratory 
was 5 JDF-Units. Antibodies to parietal cells and to 
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adrenal cortex were detected by the Standard indirect 
immunofluorescence test using cryostat sections of 
human stomach and human adrenal gland, res-
pectively 1 7. Thyroperoxidase and thyroglobin anti-
bodies were determined using a commercial ELISA kit 
(ELIAS, Freiburg). 
S t a t i s t i c analyses 
Statistical significance was determined by Chi-square 
test with Yates' correction or Fischer's exact test, 
where appropriate. Statistical differences among anti-
body levels were tested by Student's t-test. Antibody 
levels were expressed as mean ± SD. 
R E S U L T S 
The clinical and immunological characteristics of the 
study groups are summerized in Table 1. Overall anti-
bodies to G A D 6 5 and G A D 6 7 were detected in 17 
(29.3%) and 9 (15.5%) out of 58 patients with auto-
immune polyendocrinopathy Type II (Figure 1). Our 
study revealed a significant association between anti-
bodies to G A D and APS II when I D D M coexists. 
Antibodies to G A D 6 5 and G A D 6 7 were found in 13 
(44.8%) and 7 (24.1%) out of 29 diabetic patients with 
A P S II, but in only 4 (13.8%) and 2 (6.9%) out of 29 
A P S II patients without I D D M , respectively 
(p < 0.05) (Table 2). There was no correlation of G A D 
antibodies with age, sex and any particular associ-
ated organ-specific autoimmunity, besides I D D M 
(Table 3). Most strikingly, the presence of antibodies 
to G A D 6 7 was related with I D D M as part of APS II. 5 
of 9 (55.6%) patients with APS II and short-term 
I D D M (duration 0-1 year) had antibodies to G A D 6 7 
compared to 1 of 18 (5.6%) matched diabetic patients 
without coexisting endocrine autoimmune aifection 
(p < 0.01) (Table 2). Within the study groups, the de-
tection of antibodies to G A D 6 7 was strongly correlated 
to G A D 6 5 antibodies. A l l sera containing G A D 6 7 anti-
bodies were also positive for antibodies to G A D 6 5 
(p< 0.0001) (Table 3). By contrast, 8 of 58 (13.8%) 
patients with APS II and 12 of 38 (31.6%) patients 
with isolated I D D M had G A D antibodies which ex-
clusively react with the G A D 6 5 isoform. In blocking 
experiments G A D 6 7 antibodies could be completely 
preabsorbed with equal amounts of either G A D 6 7 or 
G A D 6 5 in 8 of the 9 (88.9%) G A D 6 7 antibody positive 
patients with polyendocrine autoimmunity and in two 
patients with monoglandular I D D M . Preincubation 
with G A D 6 5 resulted in a significant reduction but not 
a complete blocking of G A D 6 7 reactivity in one anti-
G A D 6 7 positive serum (serum No. 13) (Figure 2). As 
shown for G A D 6 7 antibodies, antibodies to G A D 6 5 
were increased in patients with APS II and a short 
duration of I D D M (7 of 9 [77.8%] versus 10 of 18 
[55.6%]) (p = n.s.). In addition, G A D 6 5 antibodies 
were associated with the presence of ICA (ICA in 9 of 
13 [69.2%] patients with APS II and I D D M , p < 0.02 
and in 4 of 4 [100%] patients with APS II without 
I D D M , p < 0.0001). The levels of antibodies to 
G A D 6 5 (142 ± 90 A U ) and G A D 6 7 (178 ± 95 A U ) were 
significantly higher in polyendocrine patients with 
I D D M compared to patients with isolated I D D M 
(91 ± 85 A U and 93 ± 52 A U ) (p < 0.02). Interestingly, 
we also found high level G A D 6 5 antibodies in 4 sera 
from non-diabetic patients with APS II (183 ± 77 A U ) 
(Table 3). 
Among the controls only 1 out of 6 (16.7%) patients 
with APS I and 1 of 26 (3.9%) subjects with auto-
immune thyroid disease, a 50 year old male with 
Graves' disease, were found G A D 6 5 antibody positive 
(Fig. 1A lane 7) (p < 0.005). None of the patients with 
autoimmune Addison's disease (p < 0.01), pernicious 
anaemia (p < 0.05) or of normal subjects (p < 0.0001) 
had antibodies to G A D 6 5 or G A D 6 7 (Table 2). 
Table 1 Characterisation of study groups 
Study groups Number of sera Sex (F/M) Age Autoantibodies 
Mean Range T G A T M A A C A PCA 
APS II 
without I D D M 29 20/9 41.0 18-68 21 22 18 16 
with I D D M 29 19/10 28.4 13-62 21 20 10 10 
A P S I 6 4/2 17.5 12-22 1 1 3 2 
I D D M 38 26/12 24.3 13-62 0 0 0 0 
Autoimmune thyroid 26 16/10 35.3 13-58 23 26 0 0 
Autoimmune Addison's 16 7/9 34.2 9-56 0 0 16 0 
Pernicious anaemia 7 2/5 38.6 20-50 0 0 0 7 
Controls 50 28/22 25.6 8-38 0 0 0 0 
IDDM, insulin-dependent diabetes mellitus; APS II, autoimmune polyendocrine Syndrome Type II; APS I, autoimmune polyendocrine Syndrome Type I. TGA, 
thyroglobulin antibodies; TMA, thyroid microsomal antibodies; ACA, adrenocortical antibodies; PCA, parietal cell antibodies. 
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Figure 1 Immunoprecipitation of human recombinant G A D 6 5 and G A D 6 7 . [35S]-methionine labelled G A D 6 5 (A) and G A D 6 7 (B) 
were immunopreeipitated with sera from APS II patients with IDDM (lanes 1 and 3), APS II without I D D M (lancs 2 and 4), 
Addison's disease (lane 5), pernicious anaemia (lane 6), autoimmune thyroid disease (lanes 7 and 8), and a normal control subjeet 
(lane 10). As positive controls the immunoprecipitation of mouse monoclonal antibody G A D 1 (A lane 9) and the rabbit antiserum 
K-2 (B lane 9) is demonstrated. Molecular weight markers (Mrx 10 3) are indicated on the left margin. 
D I S C U S S I O N 
The association of I D D M with Graves' disease, 
Hashimoto's thyroiditis and Addison's disease has 
been extensively documented1*2*18. In patients with 
APS II a multitude of organ-specific autoantibodies 
has been described indicating latent or overt autoim-
mune diseases. Studies in I D D M without coexisting 
organ-specific autoimmunity have shown that only the 
small isoform of G A D , G A D 6 5 , represents a major 
target antigen, whereas the detection of antibodies to 
G A D 6 7 apparently does not provide additional 
information 1 2 , 1 3 . 
In this study, we demonstrate for the first time 
significant differences in autoantibody reactivity 
against human G A D 6 5 and G A D 6 7 in patients with 
immunological and clinical features of APS II com-
pared to diabetic patients without polyendocrinopa-
thy. 56% of patients with autoimmune polyendocrine 
autoimmunity had antibodies to G A D 6 7 at the onset 
of I D D M , whereas these antibodies were rare in iso-
lated I D D M . In new onset I D D M G A D 6 7 antibodies 
have been reported in 9-18% of the cases 1 2 1 3 , but in 
those studies a discrimination between mono- and 
polyglandular failure was not performed. Since poly-
endocrine autoimmunity in I D D M is not uncommon 
we have carefully reexamined nine G A D 6 7 antibody 
positive patients with I D D M from a previous study 1 2 
for the simultaneous presence of diabetes unrelated 
organ-specific autoantibodies. Autoantibodies to thy-
roid, adrenal cortex or gastric parietal cells were found 
in six of these nine subjects (data not shown). Thus, 
only a few cases have G A D 6 7 antibodies without de-
tectable associated organ-specific antibodies. It is 
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Table 2 Prevalence of antibodies to G A D 6 5 and G A D 6 7 in patients with APS II and organ-specific autoimmune diseases 
Autoimmune manifestation Number of sera 
G A D 6 5 - A b 
Autoantibodies 
G A D 6 7 - A b ICA 
APS II 
without I D D M 29 4(13.8%) 2 (6.9%) 4(13.8%) 
with I D D M 29 13(44.8%)* 7(24.1%) 12(41.4%) 
duration 0-1 year 9 7 (77.8%)** 5 (55.6%)# 7 (77.8%) 
duration > 1 year 20 6 (30.0%) 2(10.0%) 5 (25.0%) 
(mean 12.5 years) 
APS I 6 1 (16.7%) 0 1 (16.7%) 
I D D M a 
duration 0-1 year 18 10(55.5%) 1 (5.5%) 11(61.1%) 
duration > 1 year 20 4 (20.0%) 1 (5.0%) 1 (5.0%) 
Thyroid disease 26 1 (3.9%) 0 0 
Addison's disease 16 0 0 0 
Pernicious anaemia 7 0 0 0 
Controls 50 0 0 0 
I C A , islet cell antibodies; G A D ^ - A b , antibodies to GADÖS; G A D ^ - A b , antibodies to GAD$?; I D D M , insulin-dependent diabetes mellitus; A P S II, autoimmune 
polyendocrine S y n d r o m e Type II; A P S I, autoimmune polyendocrine S y n d r o m e Type I; apatients with isolated I D D M were matched for age, sex and duration of with respect 
to APS II patients with I D D M ; *p < 0.05, ** p < 0.002 vs APS II without I D D M ; #p < 0.01 vs isolated I D D M . 
Table 3 Clinical and immunological characteristics of G A D antibody positive patients with autoimmune polyendocrine Syndrome 
Type II. G A D antibody levels are expressed in arbitrary units (AU) 
Patients 
No. 
Age 
Sex 
Autoimmune 
disease 
Duration of 
I D D M (years) 
Autoantibodies 
G A D 6 5 - A b 
(AU) 
G A D 6 7 - A b 
(AU) 
ICA 
(JDF-U) 
T G A 
(IU/ml) 
T M A 
(IU/ml) 
A C A PCA 
1 62F D M , A D 2 16 _ — 438 1031 + + -
2 42F D M , A D , G D 1 236 17 80 1111 1368 + -
3 25F D M , HT 0 44 — 20 507 3000 - -
4 33M D M , G D 0 260 178 160 — 1299 + -
5 20M D M , A D 4 28 — — — — + + 
6 57M D M , PD 25 290 268 20 3000 532 - + 
7 34F D M , HT 2 66 — — 3381 3000 + -
8 28F D M , G D 4 90 — 622 2640 - -
9 16F D M , HT, PD 1 138 278 10 3779 957 - + + 
10 17F D M , A D 0 211 247 80 — — + + 
11 22F D M , A D 0 177 — 80 — — + -
12 20F D M , A D , HT 10 132 112 320 3559 3000 + + 
13 18F D M , A D , HT 0 158 149 160 2869 2735 + -
14 65F G D , PD — 150 — 80 587 1832 - + + 
15 35F A D , HT — 100 — 20 3217 3000 + -
16 60F A D , G D — 280 70 40 670 1878 + -
17 53F A D , HT, PD - 200 113 160 731 2847 + + 
DM, insulin-dependent diabetes mellitus; AD, Addison's disease; HT, Hasimoto's thyroiditis; GD, Graves' disease; PD, pernicious disease; GAD 6 5-Ab, antibodies to 
GAD^s; GAD67-Ab, antibodies to GAD^y, ICA, islet cell antibodies; TGA, thyroglobulin antibodies; TMA, thyroid microsomal antibodies; ACA, adrenocortical antibodies; 
PCA, parietal cell antibodies; JDF-U, Juvenile Diabetes Foundation Units; +, positive; + +, strongly positive; - , negative. 
worth noting that in this study we examined only 
autoantibodies to the most frequently involved endo-
crine tissues, suggesting that in some of these anti-
G A D 6 7 positive sera other autoantibodies may coex-
ist. In striking contrast to a recent study, which 
reported on antibodies to G A D 6 5 in 5 of 5 and anti-
bodies to G A D 6 7 in 2 of 5 non-diabetic patients with 
APS I, we here found no association between G A D 
antibodies and this condi t ion 1 9 , 2 0 . The clinical fea-
tures of the subjects (age, sex and symtoms of APS I: 
mucocutaneous candidiasis, hypoparathyroidism and 
Addison's disease) seem to be similar to our patients 
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blocking of GAD67 antibody positive sera 
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Figure 2 Blocking of antibodies to G A D 6 7 in patients with autoimmune polyendocrine Syndrome Type II (•) and patients with 
isolated IDDM (A). G A D 6 7 antibody positive sera were preincubated with membrane fractions of unlabelled Sf9 cells, G A D 6 7 , or 
G A D 6 5 , and then analysed by immunoprecipitation test. serum which was only partly blocked by preincubation with GAD65. The 
antibody levels were expressed in arbitrary units (AU). The dashed line represents the cut-off (11.8 AU) for the G A D 6 7 antibodies 
(mean + 3SD of 50 normal controls). 
but the immunological characteristics differ signifi-
cantly. In the previous study all patients were detected 
as ICA positive 2 0, whereas we here observed ICA only 
in one patient with APS I, which is consistent with 
previous studies reported on ICA in only a minority of 
APS I patients 1 , 2. Thus, we suggest that the high 
frequency of G A D antibodies is explained by a selec-
tion of ICA positive patients. Since G A D antibodies 
contribute to ICA reactivity 7" 9 this would result in an 
overestimation of the prevalence of G A D antibodies. 
However, due to the small number of patients with 
APS I in both studies, which do not allow appropriate 
Statistical analysis, it is premature to draw final con-
clusions as to the role of G A D antibodies in this 
Syndrome. 
The increased prevalence of G A D 6 7 antibodies in 
APS II, observed in this study, could be explained by a 
primary autoimmune response directed to the G A D 6 7 
isoform. Immuno-precipitation, Western blot and 
Northern blot analysis have clearly shown that human 
islets contain only G A D 6 5 1 L 2 1 . In contrast, G A D 6 7 is 
widely expressed in the human central nervous System 
(CNS) and in some peripherial Organs, e.g. adrenal and 
testis2 2. Thus, the antibody response to G A D 6 7 could 
be initiated by the autoimmune affection of the above 
mentioned tissues. The adrenal glands, gonads, the 
pituitary and the hypothalamus can all represent tar-
gets in polyendocrine autoimmunity 2 3 . Although it 
cannot be excluded that G A D 6 7 is directly involved in 
polyendocrine autoimmunity, our data suggest that the 
immune recognition of G A D 6 7 may be secondary to 
humoral G A D 6 5 autoimmunity. We found higher 
prevalances of antibodies to G A D 6 5 than antibodies to 
G A D 6 7 and a restriction of G A D 6 7 antibodies to 
G A D 6 5 antibody positive individuals. Most impor-
tantly, we were able to demonstrate that in all but one 
sera G A D 6 7 antibodies could be completely blocked 
by preincubation with either G A D 6 7 or G A D 6 5 sug-
G A D ANTIBODIES IN POLYENDOCRINE A U T O I M M U N I T Y 237 
gesting that in the majority of polyendocrine patients 
G A D 6 7 antibodies are directed to common epitopes of 
both isoforms. These data agree with those obtained in 
isolated I D D M 1 2 , 1 3 ' 2 3 and, thus strongly suggest that 
G A D 6 5 also represents a major target antigen in cases 
where I D D M is part of APS IL Consistent with our 
data a high prevalence of G A D antibodies has been 
reported in patients with I D D M and autoimmune 
thyroid disease, but in that study the isoform specific-
ities were not assessed24. 
We here confirmed an association of G A D antibod-
ies with I D D M , however, we also detected four non-
diabetic patients with polyglandular Syndrome and 
high level G A D antibodies. This findings could be 
explained by a preclinical State of I D D M , but it is 
more likely that in polyendocrine patients G A D anti-
bodies can occur without autoimmune affection of the 
islets of Langerhans. Indeed, a longitudinal study has 
recently shown that some G A D antibody positive non-
diabetic subjects with polyendocrine autoimmunity do 
not develop Type 1 diabetes2 5. Furthermore, immuno-
histochemical studies failed to detect signs of insulitis 
in three G A D antibody positive patients with APS 
I I 2 6 . These data support the hypothesis that in APS II 
the autoimmune response can be directed to G A D 
expressed in non-islet cell endocrine or neuronal 
tissues. 
In this study we were able to demonstrate a hetero-
geneous humoral autoimmune response directed to 
human G A D isoforms in diabetic patients with mono-
glandular disease or coexistent autoimmune polyendo-
crinopathy. Our data suggest that the discrimination of 
antibody reactivities to G A D 6 5 and G A D 6 7 may pro-
vide information as to the potential coexistence of or 
Progression towards polyglandular failure in patients 
with I D D M . Obviously, a larger number of patients 
with APS II and longitudinal studies are required to 
clarify common and diverse mechanisms of autoim-
munity to G A D 6 5 and G A D 6 7 in different conditions. 
These studies may be important for a better under-
standing of the role of G A D autoimmunity in I D D M . 
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